| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (NCT05138458) | Myeloid Therapeutics | 2021-12-15 |
| Brentuximab Vedotin in Combination With CHEP in Patient With PTCL (NCT05006664) | Czech Lymphoma Study Group | 2021-10-01 |
| A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) (NCT05137847) | Eisai Inc. | 2021-05-24 |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders (NCT03601819) | University of Michigan Rogel Cancer Center | 2019-05-15 |
| ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT03742921) | Celgene | 2019-02-04 |
| Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) (NCT03547700) | University of Michigan Rogel Cancer Center | 2018-09-26 |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL (NCT03355768) | Jennifer Amengual | 2018-09-01 |
| Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (NCT03302728) | Peter MacCallum Cancer Centre, Australia | 2018-08-30 |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas (NCT03049449) | National Cancer Institute (NCI) | 2017-03-17 |
| 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma (NCT03051581) | Peking University Cancer Hospital & Institute | 2017-03-01 |
| Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma (NCT03051568) | Peking University Cancer Hospital & Institute | 2017-03-01 |
| Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma (NCT02535247) | Fox Chase Cancer Center | 2016-01-05 |
| A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas (NCT02788916) | Takeda | 2015-09-25 |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma (NCT02567656) | Rhizen Pharmaceuticals SA | 2015-09-01 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas (NCT02181218) | Washington University School of Medicine | 2015-02-04 |
| Cohort of Peripheral T Cell Lymphoma (NCT02364466) | Korea Cancer Center Hospital | 2015-01-01 |
| A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) (NCT01456039) | Celgene | 2011-12-01 |
| GDP in Frontline Chemotherapy for Patients With PTCL-NOS (NCT02404571) | Chinese Academy of Medical Sciences | 2011-01-01 |
| Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease (NCT01155817) | Stanford University | 2010-08-01 |
| Alemtuzumab and CHOP in T-cell Lymphoma (NCT00646854) | Aarhus University Hospital | 2008-06-01 |
| Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma (NCT01679860) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2006-11-01 |
| T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma (NCT01142674) | Associazione Angela Serra per la ricerca sul cancro | 2006-09-01 |
| A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma (NCT00211185) | Eisai Inc. | 2004-03-14 |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies (NCT00514722) | University of California, San Francisco | 2002-10-01 |